Dear Editor,

The Luminex human leukocyte antigen (HLA) single-antigen bead assay (SABA) was developed as a sensitive and specific assay to detect HLA antibodies \[[@b1-alm-2020-40-5-424]\]. However, false positive reactions may occur in the SABA due to the effect of medications such as high-dose intravenous immunoglobulin, anti-thymocyte globulin, and anti-CD20 or the presence of antibodies against denatured HLA \[[@b1-alm-2020-40-5-424]\]. Several approaches to overcome this issue have been proposed, including the use of a pretreatment reagent that adsorbs non-specific antibodies or drugs and acid treatment to distinguish specific antibodies against denatured class I HLA \[[@b2-alm-2020-40-5-424]\]. The use of acid treatment and iBead (single-antigen flow bead) has largely resolved the problem caused by antibodies against denatured class I HLA \[[@b2-alm-2020-40-5-424], [@b3-alm-2020-40-5-424]\]. However, there is no method for distinguishing antibodies against denatured class II HLA. Antibodies against denatured class II HLA have been detected at a frequency of 11% in healthy male donors \[[@b4-alm-2020-40-5-424]\]. Pan-HLA-DR reactivity is a pattern typically observed in the presence of antibodies against denatured class II HLA \[[@b5-alm-2020-40-5-424]\]. Another study found allelic bead reactions with *HLA-DRB1\*09:01, DRB3\*01:01, DRB3\*02:02, DRB3\*03:01, DPB1\*02:01, DPB1\*20:01*, and *DPB1\*28:01* for antibody reaction against denatured class II HLA \[[@b6-alm-2020-40-5-424]\].

Here, we report a case of false positive reaction with an antibody against denatured class II HLA, which showed different reactivities in screening and while using identification beads and SABA kits from different manufacturers. This study was approved by the Institutional Review Board of Severance Hospital, Seoul, Korea (4-2019-0984).

A 52-year-old female with end-stage renal disease caused by membranous nephropathy visited Severance hospital for her first kidney transplant in April 2016. She had no history of transfusion or desensitization, such as high-dose intravenous immunoglobulin, anti-thymocyte globulin, or anti-CD20, and her pregnancy history was unknown. The patient did not provide informed consent specific to this study but did provide consent for the test and signed a comprehensive agreement on the potential use of the donated sample for research purposes.

Genomic DNA was extracted from the peripheral blood using the QuickGene-Mini80 DNA Isolation System (Fujifilm, Tokyo, Japan). HLA typing was performed without delay using Lifecodes HLA SSO Typing Kits (Immucor Transplant Technology, Stamford, CT, USA), which revealed *HLA-A\*11, \*33; B\*27, \*54; DRB1\*08, \*14, DQB1\*05, \*08*. The result of the initial HLA antibody screening (LABScreen Mixed, One Lambda, Canoga Park, CA, USA) was negative for class II HLA antibodies. However, SABA using LABScreen SAB class II kit (One Lambda) showed strong pan-positive reactions \[mean fluorescence intensity (MFI) \>10,000\] against all HLA-DR, including self-HLA antigens ([Fig. 1A](#f1-alm-2020-40-5-424){ref-type="fig"}). The SABA results were not changed in the presence of the adsorption beads provided by manufacturers. The patient's serum was subsequently retested using a different SABA kit (Lifecodes LSA Class II Single Antigen Kit, Immucor), and this test revealed weak positive reactions (MFI 1,000--2,000) against DR9 and DR51 ([Fig. 1B](#f1-alm-2020-40-5-424){ref-type="fig"}). The LABScreen panel reactive antibody (PRA) (One Lambda) assay, in which the beads are coated with purified human HLA, showed positive reactions against DR15, DR16, and DR51 ([Fig. 1C](#f1-alm-2020-40-5-424){ref-type="fig"}). All assays were performed using the same initial serum, and the results were adjusted according to the results of the simultaneously tested negative control serum provided along with the kit.

Serologic evidence for the presence of donor-specific antibodies is an important criterion for Banff classification \[[@b7-alm-2020-40-5-424]\]. However, the presence of antibodies against denatured HLA has no clinical impact \[[@b8-alm-2020-40-5-424]\]. A previous study found antibodies against denatured class I HLA in 39% of patients on the kidney transplant waiting list \[[@b3-alm-2020-40-5-424]\]. These antibodies were not considered to be targeting intact cells, but rather targeting the heavy chains of HLA without β2-microglobulin, peptide, or cryptic antigens, as well as the polystyrene microbead itself \[[@b2-alm-2020-40-5-424], [@b4-alm-2020-40-5-424], [@b9-alm-2020-40-5-424]\]. Such unexpected antigenic targets may become exposed by conformational changes of HLA molecules induced by purification and bead coating of single-clone allelic HLA \[[@b2-alm-2020-40-5-424], [@b9-alm-2020-40-5-424]\], eventually resulting in false positive antibody reactions. Antibodies against denatured class II HLA have been associated with the female gender and systemic lupus erythematous \[[@b6-alm-2020-40-5-424]\]; by contrast, our patient was diagnosed as having membranous nephropathy.

In the present case, different HLA antibody reactions were observed with two SABA kits from different manufacturers (LABScreen, One Lambda and Lifecodes, Immucor). Antigenic coating process was not clearly described on the manufacturer's insert information. Immucor SABA did not show pan-DR reactivity with the sample that showed false positive reaction in One Lambda SABA ([Table 1](#t1-alm-2020-40-5-424){ref-type="table"}).

In this study, the screening (LABScreen Mixed) showed no antibody reactions and identification beads (LABScreen PRA) demonstrated weak positive reactions with HLA-DR15, -DR16, and -DR51 ([Table 1](#t1-alm-2020-40-5-424){ref-type="table"}). Both beads were coated with purified human HLA. However, the negative screening results may be due to the low sensitivity of the assay because of multiple class II HLA antigen beads being shared on a total of five beads. In addition, the sensitivity of an identification assay including class II HLA antigens on each bead could be lower than that of SABAs. For this reason, false positive reactions due to weak antibodies could not be demonstrated using screening or identification beads alone.

Flow-cytometric cross-matching to lymphocytes with known HLA antigens is another strategy to overcome false positive reactions. However, we could not perform any cross-matching tests, which is the major limitation of this study. Despite this limitation, our findings show that false positive reactions with antibodies against denatured class II HLA might differ according to the different SABA kits. This suggests an alternative approach to overcome false positivity in SABA caused by antibodies against denatured class II HLA.
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![Reactivity patterns of class II HLA antibody assays. (A) LABScreen SAB class II (One Lambda, Canoga Park, LA, USA) SABA showing pan-HLA-DR positivity. Self-HLA-DR antigens are indicated by red circles. (B) Lifecodes class II SABA (Immucor, Stamford, CT, USA) showing positivity for HLA-DR51 and -DR9. (C) PRA Identification Bead Reaction (LABScreen PRA, One Lambda) showing weak positivity for HLA-DR51, DR15, and DR16.\
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###### 

Assignment of class II HLA antibody specificity according to bead type and manufacturer

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kit used                                    Class II HLA antibody specificity identified in each essay[\*](#tfn1-alm-2020-40-5-424){ref-type="table-fn"}                                                                                                                                                                                                                                                                                 Source of antigen
  ------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  One Lambda SABA (LABScreen SAB)             Strong:\_*DR1, DR4, DR7, DR8, DR9, DR10, DR11, DR12, DR13, DR14, DR15, DR16, DR17, DR18, DR51, DR52, DR52, DR103, DQ2, DQ4, DQ5, DQ6, DQA1[\*](#tfn1-alm-2020-40-5-424){ref-type="table-fn"}01:01, DQA1[\*](#tfn1-alm-2020-40-5-424){ref-type="table-fn"}01:02, DQA1[\*](#tfn1-alm-2020-40-5-424){ref-type="table-fn"}03:01, DQA1[\*](#tfn1-alm-2020-40-5-424){ref-type="table-fn"}04:01*\   Recombinant HLA molecule
                                              Moderate: *DQ8, DQ9*\                                                                                                                                                                                                                                                                                                                                                                        
                                              Weak: *DQA1[\*](#tfn1-alm-2020-40-5-424){ref-type="table-fn"}02:01*                                                                                                                                                                                                                                                                                                                          

  Immucor SABA (Lifecodes LSA)                Weak: *DR51, DR103, DR9*                                                                                                                                                                                                                                                                                                                                                                     Recombinant HLA molecule

  One Lambda screening (LABscreen Mixed)      Negative for class II HLA antibodies                                                                                                                                                                                                                                                                                                                                                         Purified human HLA

  One Lambda identification (LABscreen PRA)   Weak: *DR15, DR16, DR51*                                                                                                                                                                                                                                                                                                                                                                     Purified human HLA
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Strong, \>10,000 MFI; Moderate, 3,000--9,999 MFI; Weak, 1,000--2,999 MFI.

Abbreviations: HLA, human leukocyte antigen; PRA, panel reactive antibody; MFI, mean fluorescence intensity; SABA, single antigen bead assay.
